Non-squamous non-small cell lung cancer
Conditions
Interventions
Experimental group:Adebelimab + chemotherapy + bevacizumab
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old, regardless of sex. two.. Resectable primary non-squamous non-small cell lung cancer in stage IIA-IIIB confirmed by histopathology or cytology (UICC/AJCC 8th edition). 3. Have not received local and systemic systemic treatment for primary lung cancer in the past. 4. At least one measurable lesion (according to RECIST 1.1). Negative driving genes such as 5.EGFR / ALK. 6.ECOG PS is 0 or 1. 7. Life expectancy = 3 months. 8. The functional level of organs must meet the following requirements: ANC = 1.5 × 10^9 / L; PLT = 90 × 10^9 / L × HB = 90 g; ALT and AST = 1.5×ULN, ALP = 2.5×ULN; BUN and Cr = 1 × ULN and creatinine clearance = 50 mL/min (Cockcroft-Gault formula); LVEF = 50%; QT interval (QTcF) corrected by Fridericia method: male < 450ms, female < 470ms;INR = 1.5×ULN, ACTT = 1.5×ULN. 9. The subjects signed an informed consent form and volunteered to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Previous anti-tumor therapy for primary lung cancer, including chemotherapy, targeting, immunity or radiotherapy. two.. Subjects with allergic or hypersensitive constitution to therapeutic drugs, subjects with autoimmune diseases. 3. There is a third space effusion (such as massive pleural effusion and ascites) that cannot be controlled by drainage or other methods. 4. Use of steroids for more than 50 days, or long-term use of steroids. 5. Uncontrolled symptomatic brain metastasis or mental abnormalities that fail to correctly express subjective symptoms. 6. Other malignant tumors occur within 5 years before enrollment, except for cervical carcinoma in situ or squamous or basal cell carcinoma of the skin that have previously been treated for the purpose of radical treatment. 7. Pregnant and lactating women who are fertile but refuse to use contraception. 8. People with a history of severe heart disease or disease, including a recorded history of congestive heart failure, high-risk uncontrollable arrhythmias, angina pectoris requiring medication, clinically defined valvular heart disease, history of severe myocardial infarction and intractable hypertension. 9. Have received allogeneic tissue / solid organ transplantation. 10. According to the researchers' judgment, there are serious hazards to the safety of the subjects, or concomitant diseases that affect the subjects' completion of the study (such as uncontrolled hypertension, diabetes, thyroid diseases, etc.). 11.The researchers determined other situations that were not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event;Major pathological response rate; | — |
Countries
China
Contacts
Public ContactRenquan Zhang
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed